Ayurveda intervention as clinical trial against COVID-19

Evaluating clinical efficacy of Guduchyadi compound in the management of Mild to Moderate COVID-19 cases along with comorbid conditions as stand alone and add on medicine. - NA

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/02/040562

Enrollment

Registered

2022-02-23

Start date

Unknown

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: U071- COVID 19 virus identified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Newly diagnosed COVID-19 confirmed by RT-PCR. 2.Mild to Moderate COVID-19 infection. 3.Comorbid conditions (HTN, Diabetes, Metabolic Syndrome) 4.Willingness and ability to comply with trial and follow-up procedures. 5.Ability to understand the nature of this trial and give written informed consent.

Exclusion criteria

Exclusion criteria: 1.Patients with severe and critical infection will be excluded. 2.Patients with severe COVID-19 infection 3.Patients with respiratory failure who need mechanical ventilation 4.Patients who cannot take drug orally 5.Inability or unwillingness to comply with study and/or follow-up procedures 6.Enrolled in other researches for treatment of COVID-19 infection

Design outcomes

Primary

Measure	Time frame
The proportion of the patients becoming RT â?? PCR Negative after being positive for covid-19Timepoint: baseline (day 0) and after 7th day (day 8) and after 10 days (day 11)	—

Secondary

Measure	Time frame
Improvement in quality of life (SF-36 proforma will be used)Timepoint: 30 days follow up after stopping ayurvedic medication	—

Countries

India

Contacts

Public ContactDr Prasanth Dharmarajan

All India Institute of Ayurveda

divyakajaria@gmail.com8826167515

Outcome results